Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176
Key Facts: Tirzepatide
- Category
- Weight Loss
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea
- Administration
- Subcutaneous injection weekly
- Typical Dose
- 5-15 mg weekly (after titration)
- Frequency
- Once weekly
- Duration
- Long-term / chronic use
Mechanism of Action
Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying.
Research Summary
SURMOUNT trials showed average weight loss of 20-26% body weight. SURMOUNT-OSA showed 25-29 fewer sleep apnea events per hour. SURPASS-2 showed superior A1C reduction compared to semaglutide. SUMMIT trial (2024-25) showed 38% reduction in CV death or worsening heart failure in HFpEF patients with obesity - data added to EU labeling Jan 2026.
FDA Approval Studies
This peptide is FDA approved. Below are the key clinical trials that supported its approval.
SURMOUNT Program (Tirzepatide for weight management)
Eli Lilly • Phase 3
5,000+ participants across SURMOUNT 1-4 trials
72 weeks
Percent change in body weight from baseline
- ✓SURMOUNT-1: Up to 22.5% weight loss with 15mg dose
- ✓SURMOUNT-2 (with diabetes): Up to 15.7% weight loss
- ✓91% of participants achieved 5%+ weight loss
- ✓57% achieved 20%+ weight loss with highest dose
SURPASS Program (Tirzepatide for Type 2 Diabetes)
Eli Lilly • Phase 3
7,000+ participants across SURPASS 1-5 trials
40-52 weeks
HbA1c reduction from baseline
- ✓Superior HbA1c reduction vs semaglutide (SURPASS-2)
- ✓Up to 2.46% HbA1c reduction from baseline
- ✓More patients reached HbA1c <7% vs comparators
- ✓Significant weight loss benefit alongside glycemic control
Dosing Information
Typical Dosingⓘ
Community experience
5-15 mg weekly (after titration)
2.5-15 mg weekly
Once weekly
Titrate up every 4 weeks. Start at 2.5 mg. Many find 10 mg effective for weight loss. GI side effects common during titration.
Research Dosingⓘ
Scientific studies
Prescribed doses per FDA labeling
Doses from Studies
2.5mg weekly (starting)
FDA Label - Mounjaro/Zepbound - Initial dose for all patients ↗
15mg weekly (max)
SURMOUNT-1 Trial, NEJM 2022 - Maximum dose - 20.9% avg weight loss ↗
Duration
Long-term / chronic use
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Morning, same day each week
Once weekly, same day and time
Food Recommendation
With or without food
Why This Timing?
Weekly injection timing should be consistent. Morning dosing helps establish routine and monitor tolerance.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea
- ●Diarrhea
- ●Vomiting
- ●Constipation
- ●Decreased appetite
- ●Abdominal pain
- ●Injection site reactions
- ●Hypoglycemia (with insulin/sulfonylureas)
- ●Pancreatitis
- ●Gallbladder problems
- ●Acute kidney injury
- ●BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2
References
- https://pubmed.ncbi.nlm.nih.gov/35658024/
- https://pubmed.ncbi.nlm.nih.gov/34170647/
- https://clinicaltrials.gov/ct2/show/NCT04184622
Research This Peptide Further
Frequently Asked Questions
What does Tirzepatide do?
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
How does Tirzepatide work?
Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying.
Is Tirzepatide FDA approved?
Yes, Tirzepatide is FDA approved. FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea
What are the side effects of Tirzepatide?
Reported side effects include: Nausea, Diarrhea, Vomiting, Constipation, Decreased appetite. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Tirzepatide?
Community-reported common dose: 5-15 mg weekly (after titration) (Once weekly). Range: 2.5-15 mg weekly. Administration: Subcutaneous injection weekly. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Tirzepatide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossOrforglipron
FDAAn oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossDulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Weight LossExenatide
FDAThe first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Weight LossWant updates on Tirzepatide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.